UK markets closed
  • FTSE 100

    6,367.58
    +4.65 (+0.07%)
     
  • FTSE 250

    19,462.71
    +66.37 (+0.34%)
     
  • AIM

    1,039.01
    +0.98 (+0.09%)
     
  • GBP/EUR

    1.1125
    -0.0086 (-0.77%)
     
  • GBP/USD

    1.3314
    -0.0042 (-0.32%)
     
  • BTC-GBP

    13,302.03
    +387.04 (+3.00%)
     
  • CMC Crypto 200

    333.27
    -4.23 (-1.25%)
     
  • S&P 500

    3,638.35
    +8.70 (+0.24%)
     
  • DOW

    29,910.37
    +37.90 (+0.13%)
     
  • CRUDE OIL

    45.53
    -0.18 (-0.39%)
     
  • GOLD FUTURES

    1,788.10
    -23.10 (-1.28%)
     
  • NIKKEI 225

    26,644.71
    +107.40 (+0.40%)
     
  • HANG SENG

    26,894.68
    +75.23 (+0.28%)
     
  • DAX

    13,335.68
    +49.11 (+0.37%)
     
  • CAC 40

    5,598.18
    +31.39 (+0.56%)
     

Sjogren's Syndrome Epidemiology Forecast to 2029 | 7MM Analysis | 1,753,781 Prevalent Cases Projected by 2029

Research and Markets
·4-min read

Dublin, Nov. 18, 2020 (GLOBE NEWSWIRE) -- The "Sjogren's Syndrome - Epidemiology Forecast to 2029" report has been added to ResearchAndMarkets.com's offering.

Through an extensive literature review and analysis of recent and historical data, the publishing team's epidemiologists have provided the most reliable and up-to-date forecast for SS in the 7MM. The team's epidemiologists performed a literature review, in both English and country-specific languages, to provide the most thorough search for SS data. The forecast provides detailed, clinically relevant segmentations of the SS population, with pSS prevalence, sSS prevalence, and ESSDAI proportions included in all markets.

The epidemiologists have forecast the diagnosed prevalent cases of SS in the 7MM to increase from 1,630,861 in 2019, to 1,753,781 in 2029, with an annual growth rate (AGR) of 0.75%.

In 2019, the epidemiologists estimated 1,111,294 diagnosed prevalent cases of pSS and 519,567 diagnosed prevalent cases of sSS. For systemic involvement of pSS defined by ESSDAI, the epidemiologists showed across the 7MM, the largest proportion of cases reported low-activity (ESSDAI&lessThan; 5) (70.20%) and the smallest proportion of cases reporting high-activity (ESSDAI?14) (5.59%).

The epidemiologists predict that if other markets identify and address gaps in the diagnosis of SS as well as advocate for more dedicated SS research, similar to the UK, the rate of diagnosis will increase over time.

Report Scope

  • The Sjogren's Syndrome Epidemiology Report provides an overview of the risk factors, comorbidities, and global trends of Sjogren's Syndrome (SS) in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).

  • The report includes a 10-year epidemiological forecast for diagnosed prevalent cases of pSS and sSS, with pSS segmented by sex and by age (18-29 years and for ages 30 years and older by 10-year age groups up to 80 years and older). Diagnosed prevalent cases of pSS are further segmented by systemic activity level using the ESSDAI classification.

  • The SS epidemiology report is written and developed by Masters- and PhD-level epidemiologists.

  • The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in SS.

The SS Epidemiology series will allow you to:

  • Develop business strategies by understanding the trends shaping and driving the global SS markets.

  • Quantify patient populations in the global SS markets to improve product design, pricing, and launch plans.

  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for SS therapeutics in each of the markets covered.

  • Understand magnitude of systemic involvement of pSS defined by ESSDAI.

Key Topics Covered

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Sjogren's Syndrome: Executive Summary
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Reports

3 Epidemiology
3.1 Disease Background
3.2 Risk Factors and Comorbidities
3.3 Global and Historical Trends
3.3.1 Diagnosed Prevalence of SS (%)
3.4 Forecast Methodology
3.4.1 Sources
3.4.2 Sources Not Used
3.4.3 Forecast Assumptions and Methods
3.5 Epidemiological Forecast for SS (2019-2029)
3.5.1 Diagnosed Prevalent Cases of pSS
3.5.2 Diagnosed Prevalent Cases of sSS
3.5.3 Age-Specific Diagnosed Prevalent Cases of pSS
3.5.4 Sex-Specific Diagnosed Prevalent Cases of pSS
3.5.5 Diagnosed Prevalent Cases of pSS by ESSDAI
3.6 Discussion
3.6.1 Epidemiological Forecast Insight
3.6.2 Limitations of Analysis
3.6.3 Strengths of Analysis

4 Appendix
4.1 Bibliography
4.2 About the Authors
4.2.1 Epidemiologist
4.2.2 Reviewers
4.2.3 Director of Epidemiology and Global Director of Therapy Analysis and Epidemiology
4.2.4 Global Head and EVP of Healthcare Operations and Strategy
4.3 About the Publisher
4.4 Contact

For more information about this report visit https://www.researchandmarkets.com/r/hzhagu

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900